Why the study?
Do Angiotensin AT1 receptor antagonists offer clinical benefits over ACE inhibitors in hypertension, cardiac and vascular remodelling, and kidney insufficiency?
Do Angiotensin AT1 receptor antagonists offer clinical benefits over ACE inhibitors in hypertension, cardiac and vascular remodelling, and kidney insufficiency?
This review outlines the theoretical pharmacological advantages of ARBs over ACE inhibitors, highlighting the need for long-term clinical trials to confirm these potential benefits.
No takes yet. Share an insight, caveat, or question.
ARBs should not replace ACE inhibitors in practice on theoretical grounds alone; leaves open whether long-term trials will confirm clinical superiority.
Gasparo et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: